Optimization of an anti-HER2 nanobody expression using the Taguchi method.

Area of Science:

• Biotechnology
• Molecular Biology
• Immunotherapy

Background:

• Whole antibodies face limitations in cancer immunotherapy, driving the development of novel biomolecules like nanobodies.
• Recombinant nanobodies offer a promising alternative with potential for improved therapeutic applications.

Purpose of the Study:

• To optimize the overexpression of a recombinant anti-HER2 nanobody using the Taguchi methodology.
• To identify the ideal conditions for temperature, induction, culture media, vector, and host strain for enhanced nanobody production.

Main Methods:

• Utilized Taguchi methodology to design 16 experiments evaluating multiple expression variables.
• Assessed total protein via Bradford assay and SDS-PAGE, quantified nanobody concentration using size exclusion HPLC.
• Confirmed nanobody expression using Western blotting and evaluated binding activity with flow cytometry and ELISA.

Main Results:

• Identified optimal conditions: SHuffle strain, LB medium, 0.4 mM IPTG induction for 18 hours at 24°C.
• Achieved a 9% increase in production yield (25.4 mg/L) under optimized conditions compared to the highest prior expression setting.
• Demonstrated improved protein binding affinity in flow cytometry and ELISA assays with optimized nanobody production.

Conclusions:

• The Taguchi method effectively optimized recombinant nanobody production conditions.
• Optimized production enhances both yield and biological activity of anti-HER2 nanobodies.
• Findings support further research into cost-effective recombinant nanobody production for therapeutic applications.